Nonetheless, the promising results obtained from [64Cu]NODAGA-CG34 in preclinical models of lung diseases and the high affinity of CG34 to human CMKLR1 along with the clinical relevance of CMKLR1 as a biomarker of MDMφ in patients with COVID-19 (16) and IPF will lay a solid foundation for future Investigational New Drug application to enable the first-in-human use of this tracer in fibrotic lung diseases. This evidence concerns the gene CMKLR1 and lung disorder.